Get started
Author

Muhammad Hussnain Sadiq

Observed name: Muhammad Hussnain Sadiq
ORCID: 0009-0003-9499-2636
Observed ORCID: 0009-0003-9499-2636
OpenAlex ID: A5127799563
Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0
2026 · Jennifer L. Caswell-Jin, Mark R. Somerfield, et al. · Journal of Clinical Oncology · 2
Automated Phenotypic Characterization in Rare Hematologic Malignancies Using a Large Language Model–Based Framework
2026 · Muhammad Ali Khan, Umair Ayub, et al. · medRxiv
PDF
Hybrid AI framework for automated prostate cancer disease state ascertainment from real-world electronic health records.
2026 · Umair Ayub, Syed Arsalan Ahmed Naqvi, et al. · Journal of Clinical Oncology
Differential quality of life (QoL) with novel hormonal therapy (NHT) in metastatic castration-sensitive prostate cancer (mCSPC): A network meta-analysis of randomized clinical trials.
2026 · Muhammad Uzair Sarfraz, Syed Arsalan Ahmed Naqvi, et al. · Journal of Clinical Oncology
Cardiovascular toxicity with androgen-receptor pathway inhibitors in metastatic prostate cancer: A meta-analysis of randomized trials.
2026 · Muhammad Hussnain Sadiq, Muhammad Uzair Sarfraz, et al. · Journal of Clinical Oncology
Leveraging large language models (LLM) to guide adjuvant treatment recommendations for renal cell carcinoma (RCC) after nephrectomy.
2026 · Fouad Nahhat, Arshad Mohammed, et al. · Journal of Clinical Oncology
Comparative real-world survival and prescription patterns of darolutamide versus apalutamide in non-metastatic hormone-resistant prostate cancer.
2026 · Muhammad Umar Afzal, Lanyu Mi, et al. · Journal of Clinical Oncology
PDF
Automated Phenotypic Characterisation In Rare Haematological Malignancies Using A Large Language Model-Based Framework: A Retrospective Diagnostic Accuracy Study
2026 · Muhammad Ali Khan, Umair Ayub, et al. · SSRN Electronic Journal
Works count: 8
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type